Figure 2

The expression of the hCD40L transgene does not abrogate oncolytic efficacy. (a) Human lung adenocarcinoma cells (A549, CD40-), (b) bladder cancer cells (EJ, CD40+) and (c) breast cancer cells (M4A4-LM3, CD40-) were infected with different concentrations of replication-competent vvdd-tdtomato or vvdd-hCD40L-tdtomato. Three days later, cell viability was measured using an MTS assay.